Call it “romantic persistence.” Positive results of a Phase 3 clinical trial have spurred a New Drug Application resubmission that may pay off for Sprout….and millions of women.
Sprout Pharmaceuticals, a Raleigh-based pharmaceutical company, has resubmitted the New Drug Application (NDA) for flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. If approved, Sprout’s version of “Pink Viagra” would be the first FDA approved treatment for HSDD in pre-menopausal women. Read more
